Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Does aspirin prevent colorectal adenomas?

Two studies in this week's New England Journal of Medicine find that aspirin is associated with a reduction in the incidence of colorectal adenomas.

News image

fiogf49gjkf04

Experimental and observational studies suggest that regular aspirin use may decrease the risk of colorectal adenomas.

In this study, researchers from the United States conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas.

The research team randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo.

1 or more adenomas were found in 17% of patients in the aspirin group and in 27% in the placebo group.
New England Journal of Medicine

They determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations.

The team adjusted relative risks for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy.

The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis.

The researchers determined that a total of 517 patients had at least 1 colonoscopic examination a median of 12.8 months after randomization.

The team found 1 or more adenomas in 17% of patients in the aspirin group and in 27% in the placebo group.

Furthermore, the mean number of adenomas was lower in the aspirin group than the placebo group (0.30 versus 0.49, respectively).

The team also found that the adjusted relative risk of any recurrent adenoma in the aspirin group, compared with the placebo group, was 0.65.

Additionally, the team found that the time to the detection of a first adenoma was longer in the aspirin group than in the placebo group.

Dr Robert Sandler’s team concluded, “Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer”.

In a separate but related study in the same publication, researchers performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas.

They assigned 1121 patients with a recent history of histologically documented adenomas to receive placebo, 81 mg of aspirin, or 325 mg of aspirin daily.

According to the protocol, follow-up colonoscopy was to be performed approximately 3 years after the qualifying endoscopy.

The team compared the groups with respect to the risk of 1 or more neoplasms (adenomas or colorectal cancer) at least 1 year after randomization.

The researchers found that reported adherence to study medications, and avoidance of nonsteroidal anti-inflammatory drugs were both excellent.

They performed follow-up colonoscopy at least 1 year after randomization in 97% of patients.

The team found that the incidence of 1 or more adenomas was 47% in the placebo group, 38% in the 81-mg aspirin group, and 45% in the 325-mg aspirin group.

Unadjusted relative risks of any adenoma were 0.81 in the 81-mg group and 0.96 in the 325-mg group.

For advanced neoplasms, the team found that the respective relative risks were 0.59 and 0.83.

Dr John Baron’s team concluded, “Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel”.

New Engl J Med 2003; 348(10): 883-90, 891-99
07 March 2003

Go to top of page Email this page Email this page to a colleague

 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Worldwide H.pylori prevalence
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us